Loading...
Loading...
Loading...
Loading...
Cellagen Technology
gamma-secretase inhibitor
YO-01027 (Dibenzazepine, DBZ) is a dipeptidic g-secretase inhibitor with IC50 of 2.6 and 2.9 nM for APPL and Notch, respectively. YO-01027 targets the Presenilin fragment. Increasing concentrations of YO-01027 administered to APPl- or Notch-expressing cells leads to the progressive accumulation of APPL C-terminal fragments and a decrease in NICD production in a dose-dependent manner. [1]
In an in vitro model of human corneal and conjunctival epithelial cell differentation, YO-01027 impaired MUC16 biosynthesis in a concentration-dependent manner. [2]
In oncology models, YO-01027 preferentially inhibited Notch and significantly decreased MCF7 tumors and increased latency compared with control mice. [3]
Cellagen Technology
gamma-secretase inhibitor
YO-01027 (Dibenzazepine, DBZ) is a dipeptidic g-secretase inhibitor with IC50 of 2.6 and 2.9 nM for APPL and Notch, respectively. YO-01027 targets the Presenilin fragment. Increasing concentrations of YO-01027 administered to APPl- or Notch-expressing cells leads to the progressive accumulation of APPL C-terminal fragments and a decrease in NICD production in a dose-dependent manner. [1]
In an in vitro model of human corneal and conjunctival epithelial cell differentation, YO-01027 impaired MUC16 biosynthesis in a concentration-dependent manner. [2]
In oncology models, YO-01027 preferentially inhibited Notch and significantly decreased MCF7 tumors and increased latency compared with control mice. [3]
